<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01755858</url>
  </required_header>
  <id_info>
    <org_study_id>SPIRI-225</org_study_id>
    <nct_id>NCT01755858</nct_id>
  </id_info>
  <brief_title>Effects of Intravenous Bendavia™ on Reperfusion Injury in Patients Undergoing Angioplasty of the Renal Artery</brief_title>
  <acronym>EVOLVE</acronym>
  <official_title>A Phase 2a, Placebo-controlled Trial to Evaluate the Impact of Intravenous Bendavia™ on Ischemia Reperfusion Injury in Atherosclerotic Renal Artery Stenosis in Patients Undergoing Percutaneous Transluminal Angioplasty of the Renal Artery</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Stealth BioTherapeutics Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Stealth BioTherapeutics Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled&#xD;
      study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV&#xD;
      elamipretide for reduction of reperfusion injury in subjects with Atherosclerotic Renal&#xD;
      Artery Stenosis (ARAS), who are undergoing percutaneous transluminal angioplasty of the renal&#xD;
      artery (PTRA).&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This was a Phase 2a prospective, single center, randomized, double-blind, placebo-controlled&#xD;
      study designed to assess the efficacy, pharmacokinetics, safety and tolerability of IV&#xD;
      elamipretide for reduction of reperfusion injury in subjects with ARAS, who are undergoing&#xD;
      percutaneous transluminal angioplasty of the renal artery (PTRA).&#xD;
&#xD;
      The randomization (1:1 active:placebo) was stratified by a diagnosis of diabetes mellitus.&#xD;
      Participants received either 0.05 mg/kg/h elamipretide or matching placebo, administered as&#xD;
      an IV infusion at 60 mL/h infused 30 minutes before and continued 3 hours after PTRA of the&#xD;
      renal artery. After completion of the PTRA and stenting, subjects were to receive standard&#xD;
      treatment.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <start_date>December 2012</start_date>
  <completion_date type="Actual">May 2016</completion_date>
  <primary_completion_date type="Actual">December 2015</primary_completion_date>
  <phase>Phase 1/Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.</measure>
    <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
    <description>Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.</measure>
    <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
    <description>Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA</measure>
    <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
    <description>Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA</measure>
    <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
    <description>Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.</measure>
    <time_frame>Baseline (Pre-PTRA) and 8 (+4) weeks post-PTRA</time_frame>
    <description>Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA</measure>
    <time_frame>Baseline (Pre-PTRA) , 27 hours post-PTRA and 8 weeks post-PTRA</time_frame>
    <description>Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA</measure>
    <time_frame>27H post PTRA and 8 weeks Post PTRA</time_frame>
    <description>Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA</measure>
    <time_frame>Pre-PTRA and 27 hours post-PTRA and 8 weeks post-PTRA</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean Change in Diastolic Blood Pressure</measure>
    <time_frame>Pre-PTRA, immediately post-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA</time_frame>
    <description>Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">16</enrollment>
  <condition>Renal Artery Obstruction</condition>
  <condition>Hypertension, Renovascular</condition>
  <condition>Ischemia Reperfusion Injury</condition>
  <arm_group>
    <arm_group_label>Bendavia</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Bendavia</intervention_name>
    <arm_group_label>Bendavia</arm_group_label>
    <other_name>MTP-131</other_name>
    <other_name>Elamipretide</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  ≥40 and ≤80 years old.&#xD;
&#xD;
          -  Patients with hypertension (systolic blood pressure [BP] &gt;155 mm Hg) and/or requiring&#xD;
             2 or more antihypertensive medications: no restrictions will be placed on&#xD;
             antihypertensive agents, although loop diuretics will be temporarily changed to&#xD;
             diluting site agents (eg, hydrochlorothiazide, indapamide, metolazone) prior to each&#xD;
             blood oxygen level-dependent magnetic resonance imaging (BOLD-MRI) study performed&#xD;
             during the trial, unless, in the judgment of the Investigator, the change represents a&#xD;
             hazard to the patient. ARAS patients will be identified based upon radiologic and&#xD;
             clinical criteria suggestive of renovascular hypertension and/or hemodynamically&#xD;
             significant renovascular disease &gt;60% lumen occlusion (determined by quantitative&#xD;
             computed tomography angiography or Doppler ultrasound velocity &gt;200 cm/sec).&#xD;
&#xD;
          -  Have an estimated glomerular filtration rate of ≥15 ml/min/1.73 m2 calculated using&#xD;
             the Modification of Diet in Renal Disease (MDRD) formula.&#xD;
&#xD;
          -  Have no contraindications to angiography such as severe contrast allergy.&#xD;
&#xD;
          -  Have no contraindications to non-contrast magnetic resonance evaluations such as a&#xD;
             pacemaker or magnetically active metal fragments.&#xD;
&#xD;
          -  Able to comply with protocol.&#xD;
&#xD;
          -  Women of childbearing age must:&#xD;
&#xD;
          -  Have a negative pregnancy serum human chorionic gonadotropin test prior to receiving&#xD;
             study drug.&#xD;
&#xD;
          -  Agree to use two forms of contraception for 3 months following receipt of the study&#xD;
             drug.&#xD;
&#xD;
          -  Men who are sexually active and able to father a child, must agree to use one of the&#xD;
             birth control methods listed below for the entire study and for at least 2 months&#xD;
             after receiving the study drug:&#xD;
&#xD;
          -  Barrier methods (such as a condom or diaphragm) used with a spermicide.&#xD;
&#xD;
          -  Hormonal methods used by his partner, such as birth control pills, patches,&#xD;
             injections, vaginal ring, or implants.&#xD;
&#xD;
          -  Intrauterine device (IUD) used by his partner.&#xD;
&#xD;
          -  Abstinence (no sex).&#xD;
&#xD;
          -  Competent and able to provide written informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Advanced chronic kidney disease defined as either Stage 5 or end-stage renal disease&#xD;
             requiring dialysis.&#xD;
&#xD;
          -  Have other clinically significant abnormalities or laboratory results that would, in&#xD;
             the opinion of the investigators, compromise the safety of the patient including&#xD;
             evidence of diabetic ketoacidosis, paraproteinemia, or triglycerides above 600 mg/dL.&#xD;
&#xD;
          -  Clinically significant medical conditions within the six months before administration&#xD;
             of Bendavia (e.g., cancer, stroke, myocardial infarction, active angina, congestive&#xD;
             heart failure) that would, in the opinion of the investigators, compromise the safety&#xD;
             of the patient.&#xD;
&#xD;
          -  Have received an investigational drug within thirty (30) days of baseline.&#xD;
&#xD;
          -  Have a serum sodium &lt;135 mmol/L on the day of, and prior to, the PTRA.&#xD;
&#xD;
          -  Are pregnant or breast feeding.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Stephen C Textor, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Mayo Clinic</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Richard Straube, MD</last_name>
    <role>Study Director</role>
    <affiliation>Stealth BioTherapeutics Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>August 2020</verification_date>
  <study_first_submitted>December 19, 2012</study_first_submitted>
  <study_first_submitted_qc>December 19, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 24, 2012</study_first_posted>
  <results_first_submitted>July 24, 2020</results_first_submitted>
  <results_first_submitted_qc>August 10, 2020</results_first_submitted_qc>
  <results_first_posted type="Actual">August 11, 2020</results_first_posted>
  <last_update_submitted>August 10, 2020</last_update_submitted>
  <last_update_submitted_qc>August 10, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">August 11, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>elamipretide</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Renal Artery Obstruction</mesh_term>
    <mesh_term>Hypertension, Renovascular</mesh_term>
    <mesh_term>Reperfusion Injury</mesh_term>
    <mesh_term>Ischemia</mesh_term>
    <mesh_term>Wounds and Injuries</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Bendavia</title>
          <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="7"/>
                <participants group_id="P2" count="9"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="6"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </milestone>
          </milestone_list>
          <drop_withdraw_reason_list>
            <drop_withdraw_reason>
              <title>Adverse Event</title>
              <participants_list>
                <participants group_id="P1" count="1"/>
                <participants group_id="P2" count="1"/>
              </participants_list>
            </drop_withdraw_reason>
          </drop_withdraw_reason_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Bendavia</title>
          <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="7"/>
            <count group_id="B2" value="9"/>
            <count group_id="B3" value="16"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="66.1" spread="6.41"/>
                    <measurement group_id="B2" value="72.6" spread="7.78"/>
                    <measurement group_id="B3" value="69.8" spread="7.72"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="7"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="3"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="9"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Diabetes Mellitus Status</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Positive</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="3"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Negative</title>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="13"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.</title>
        <description>Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..</description>
        <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
        <population>All participants for whom GFR by iothalamate clearance was measured at Baseline (pre-PTRA) and 8 weeks post-PTRA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Glomerular Filtration Rate (GFR), as Measured by Iothalamate Clearance, at Baseline (Pre-percutaneous Renal Artery Angioplasty and 8 Weeks Post-PTRA.</title>
          <description>Change in mean glomerular filtration rate (GFR), as measured by iothalamate clearance, from baseline (pre-percutaneous renal artery angioplasty, or pre-PTRA) and 8 weeks post-PTRA..</description>
          <population>All participants for whom GFR by iothalamate clearance was measured at Baseline (pre-PTRA) and 8 weeks post-PTRA.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="6"/>
                <count group_id="O2" value="8"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.3" spread="12.14"/>
                    <measurement group_id="O2" value="12.0" spread="23.84"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.</title>
        <description>Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.</description>
        <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
        <population>All participants with stented quantifiable kidneys for whom GFR by MDCT was measured at Baseline (pre-PTRA) and 8 weeks post-PTRA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Glomerular Flow Rate as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.</title>
          <description>Change in mean glomerular flow rate as measured using Multi-Detector Computed Tomography (MDCT) at baseline (pre-PTRA) and 8 weeks post-PTRA, stented quantifiable scanned kidneys.</description>
          <population>All participants with stented quantifiable kidneys for whom GFR by MDCT was measured at Baseline (pre-PTRA) and 8 weeks post-PTRA.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Single Kidney</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.238" spread="0.2557"/>
                    <measurement group_id="O2" value="0.010" spread="0.0552"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Single Kidney</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.012" spread="0.1487"/>
                    <measurement group_id="O2" value="0.120" spread="0.1600"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA</title>
        <description>Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.</description>
        <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
        <population>All participants for whom regional perfusion was measured by MDCT with stented quantifiable scanned kidneys at Baseline (pre-PTRA) and 8 weeks post-PTRA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Regional Perfusion as Measured by MDCT at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA</title>
          <description>Change in mean regional perfusion as measured by Multi-Detector Computed Tomography (MDCT) Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys.</description>
          <population>All participants for whom regional perfusion was measured by MDCT with stented quantifiable scanned kidneys at Baseline (pre-PTRA) and 8 weeks post-PTRA.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Cortical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.266" spread="0.9341"/>
                    <measurement group_id="O2" value="-0.816" spread="0.6614"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Medullary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.242" spread="0.4143"/>
                    <measurement group_id="O2" value="-0.082" spread="0.2541"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Cortical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.614" spread="1.2390"/>
                    <measurement group_id="O2" value="0.220" spread="0.9112"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Medullary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.150" spread="0.3788"/>
                    <measurement group_id="O2" value="0.156" spread="0.5184"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA</title>
        <description>Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys</description>
        <time_frame>Baseline (pre-PTRA) and 8 weeks post-PTRA</time_frame>
        <population>All participants for whom renal blood flow as measured by MDCT was measured in stented quantifiable scanned kidneys at baseline and 8 weeks post-PTRA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Renal Blood Flow as Measured Using Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA</title>
          <description>Change in mean renal blood flow (ml/minute) as measured using Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA for stented quantifiable scanned kidneys</description>
          <population>All participants for whom renal blood flow as measured by MDCT was measured in stented quantifiable scanned kidneys at baseline and 8 weeks post-PTRA.</population>
          <units>mL/min</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Cortical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="85.056" spread="63.2943"/>
                    <measurement group_id="O2" value="-28.406" spread="54.8919"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Medullary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.658" spread="20.3007"/>
                    <measurement group_id="O2" value="-10.204" spread="21.2044"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="91.712" spread="82.4794"/>
                    <measurement group_id="O2" value="-38.608" spread="43.4011"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Cortical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="23.928" spread="64.4891"/>
                    <measurement group_id="O2" value="35.090" spread="59.9470"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Medullary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.610" spread="14.4951"/>
                    <measurement group_id="O2" value="5.930" spread="19.0256"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Total</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="27.538" spread="78.0728"/>
                    <measurement group_id="O2" value="41.018" spread="75.6824"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.</title>
        <description>Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.</description>
        <time_frame>Baseline (Pre-PTRA) and 8 (+4) weeks post-PTRA</time_frame>
        <population>All participants for whom renal volume was measured at baseline (Pre-PTRA) and 8 weeks post-PTRA in stented quantifiable kidneys.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Change in Mean Renal Volume as Measured by Multi-Detector Computed Tomography (MDCT) at Baseline (Pre-PTRA) and 8 Weeks Post-PTRA.</title>
          <description>Change in mean renal volume as measured by Multi-Detector Computed Tomography (MDCT) at Baseline (pre-PTRA) and 8 weeks post-PTRA.</description>
          <population>All participants for whom renal volume was measured at baseline (Pre-PTRA) and 8 weeks post-PTRA in stented quantifiable kidneys.</population>
          <units>mL</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="5"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Right Total Kidney Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.270" spread="12.8218"/>
                    <measurement group_id="O2" value="4.708" spread="13.7198"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Total Kidney Volume</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.090" spread="17.6951"/>
                    <measurement group_id="O2" value="10.220" spread="8.9447"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Cortical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.372" spread="10.5438"/>
                    <measurement group_id="O2" value="9.840" spread="13.1156"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Right Medullary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.162" spread="4.7616"/>
                    <measurement group_id="O2" value="-5.132" spread="7.0670"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Cortical</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.534" spread="15.0459"/>
                    <measurement group_id="O2" value="10.100" spread="10.8462"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Left Medullary</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.558" spread="3.1016"/>
                    <measurement group_id="O2" value="0.120" spread="8.6277"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA</title>
        <description>Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.</description>
        <time_frame>Baseline (Pre-PTRA) , 27 hours post-PTRA and 8 weeks post-PTRA</time_frame>
        <population>All participants for whom fractional renal oxygenation, axial aspect, in stented kidneys was measured at baseline, 27 hours post-PTRA and 8 weeks post-PTRA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Renal Oxygenation, Axial Aspect, in Stented Kidneys From Baseline (Pre-PTRA), and 27 Hours Post-PTRA and 8 Weeks Post-PTRA</title>
          <description>Mean change in renal oxygenation, axial aspect, in stented kidneys between baseline (pre-PTRA), and 27 hours post-PTRA and 8 weeks post-PTRA as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging.</description>
          <population>All participants for whom fractional renal oxygenation, axial aspect, in stented kidneys was measured at baseline, 27 hours post-PTRA and 8 weeks post-PTRA.</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>AxialRightPrefurosemideFractHyp%&gt;20 27H Post PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.440" spread="34.6825"/>
                    <measurement group_id="O2" value="16.708" spread="19.4980"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialRightPrefurosemideFractHyp%&gt;20; 8Wk Post PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.380" spread="8.5013"/>
                    <measurement group_id="O2" value="-10.892" spread="15.370"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialRightPrefurosemideFractHyp%&gt;30 27H PostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.206" spread="9.4875"/>
                    <measurement group_id="O2" value="11.600" spread="17.8192"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialRightPrefurosemideFractHyp%&gt;30 8Wk PostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.120" spread="2.7426"/>
                    <measurement group_id="O2" value="-1.840" spread="2.8693"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialRightPostfurosemideFracHyp%&gt;20 27HPostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="24.280" spread="27.6206"/>
                    <measurement group_id="O2" value="13.854" spread="26.2292"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialRightPostfurosemideFracHyp%&gt;20 8WkPostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="28.625" spread="8.9537"/>
                    <measurement group_id="O2" value="-7.560" spread="13.5471"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialRightPostfurosemideFracHyp %30 27H Post PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.080" spread="7.6904"/>
                    <measurement group_id="O2" value="13.490" spread="21.1322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialRightPostfurosemideFracHyp%&gt;30 8WkPost PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.400" spread="2.9473"/>
                    <measurement group_id="O2" value="-1.370" spread="3.4412"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeftPrefurosemide Frac Hyp%&gt;20 27H Post PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.320" spread="21.7694"/>
                    <measurement group_id="O2" value="12.767" spread="26.0745"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeftPrefurosemide Frac Hyp%&gt;20 8Wk Post PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.420" spread="17.3066"/>
                    <measurement group_id="O2" value="-8.160" spread="16.4477"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeft Prefurosemide Frac Hyp %&gt;30 27H PostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.128" spread="3.0154"/>
                    <measurement group_id="O2" value="16.938" spread="25.4089"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeft PrefurosemideFrac Hyp %&gt;30 8Wk PostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.602" spread="7.1510"/>
                    <measurement group_id="O2" value="-6.360" spread="11.3054"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeft Post-FurosemideFrac Hyp%&gt;20 27HPostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.148" spread="21.0184"/>
                    <measurement group_id="O2" value="14.083" spread="34.6825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeft Post-FurosemideFrac Hyp%&gt;20 8WkPostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.012" spread="17.3829"/>
                    <measurement group_id="O2" value="-14.220" spread="13.303"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeft Post-FurosemideFrac Hyp%&gt;30 27HPostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-1.874" spread="2.5111"/>
                    <measurement group_id="O2" value="18.757" spread="27.1441"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>AxialLeft Post-FurosemideFrac Hyp%&gt;30 8WkPostPTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.858" spread="7.0087"/>
                    <measurement group_id="O2" value="-5.704" spread="8.3550"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA</title>
        <description>Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia</description>
        <time_frame>27H post PTRA and 8 weeks Post PTRA</time_frame>
        <population>All participants for whom fractional renal oxygenation, coronal aspect, in stented kidneys was measured at baseline, 27 hours post-PTRA and 8 weeks post-PTRA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Renal Oxygenation, Coronal Aspect, in Stented Kidneys Between Baseline Pre-PTRA, 27 Hours Post-PTRA and 8 Weeks Post-PTRA</title>
          <description>Mean change in renal oxygenation, coronal aspect, in stented kidneys between baseline (pre-PTRA) and 27 hours post-PTRA or 8 weeks post-PTRA, as measured by calculation of fractional hypoxia using blood oxygenation level-dependent magnetic resonance (BOLD-MR) imaging, with and without Bendavia</description>
          <population>All participants for whom fractional renal oxygenation, coronal aspect, in stented kidneys was measured at baseline, 27 hours post-PTRA and 8 weeks post-PTRA.</population>
          <units>s^-1</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="5"/>
                <count group_id="O2" value="6"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>CoronalRtFractHypoxia% &gt;20Prefuros.27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="20.314" spread="33.3525"/>
                    <measurement group_id="O2" value="9.083" spread="17.3368"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalRtFractHypoxia% &gt;20Prefuros.8WkPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4.140" spread="16.4690"/>
                    <measurement group_id="O2" value="-2.220" spread="7.5549"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalRtFractHypoxia% &gt;30Prefuros.27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="10.800" spread="9.6734"/>
                    <measurement group_id="O2" value="9.250" spread="30.6001"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalRtFractHypoxia% &gt;30Prefuros8WkPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.300" spread="10.1403"/>
                    <measurement group_id="O2" value="-2.852" spread="11.1986"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalRtFractHypoxia% &gt;20Postfuros27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="29.800" spread="33.5328"/>
                    <measurement group_id="O2" value="3.840" spread="22.4825"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalRtFractHypoxia% &gt;20Postfuros8WKPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.233" spread="7.5142"/>
                    <measurement group_id="O2" value="-5.220" spread="4.6018"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalRtFractHypoxia% &gt;30Postfuros27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="12.875" spread="13.2666"/>
                    <measurement group_id="O2" value="11.458" spread="32.8826"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalRtFractHypoxia% &gt;30Postfuros8WkPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="3"/>
                    <count group_id="O2" value="5"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="2.233" spread="3.5119"/>
                    <measurement group_id="O2" value="-8.158" spread="16.5393"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;20Prefuros.27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="5.000" spread="23.7674"/>
                    <measurement group_id="O2" value="6.033" spread="31.1820"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;20Prefuros.8WkPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-3.125" spread="10.2970"/>
                    <measurement group_id="O2" value="-0.525" spread="12.5077"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;30Prefuros.27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.000" spread="8.9272"/>
                    <measurement group_id="O2" value="22.615" spread="35.6971"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;30Prefuros.8WkPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.275" spread="4.4650"/>
                    <measurement group_id="O2" value="-1.525" spread="12.3605"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;20Postfuros.27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="6.240" spread="24.5671"/>
                    <measurement group_id="O2" value="6.783" spread="29.1337"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;20Postfuros.8WkPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.375" spread="9.2525"/>
                    <measurement group_id="O2" value="-0.700" spread="14.7384"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;30Postfuros.27HPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="5"/>
                    <count group_id="O2" value="6"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.080" spread="7.3145"/>
                    <measurement group_id="O2" value="20.345" spread="31.5024"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>CoronalLeftFractHypoxia% &gt;30Postfuros.8WkPost-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="4"/>
                    <count group_id="O2" value="4"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-0.250" spread="2.0873"/>
                    <measurement group_id="O2" value="-4.225" spread="12.7899"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA</title>
        <time_frame>Pre-PTRA and 27 hours post-PTRA and 8 weeks post-PTRA</time_frame>
        <population>All participants for whom systolic blood pressure was measured at baseline (pre-PTRA) and 27 hours post-PTRA, or 8(+4) weeks post-PTRA.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.&#xD;
Bendavia</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.&#xD;
Placebo</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Systolic Blood Pressure Values (mmHg) From Pre-PTRA, Immediately Post-PTRA, 27 Hours and 8 (+4) Weeks Post-PTRA</title>
          <population>All participants for whom systolic blood pressure was measured at baseline (pre-PTRA) and 27 hours post-PTRA, or 8(+4) weeks post-PTRA.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>27 Hours Post-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-2.9" spread="14.78"/>
                    <measurement group_id="O2" value="-3.8" spread="15.69"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 weeks Post PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="13.2" spread="19.88"/>
                    <measurement group_id="O2" value="-0.8" spread="30.83"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Secondary</type>
        <title>Mean Change in Diastolic Blood Pressure</title>
        <description>Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.</description>
        <time_frame>Pre-PTRA, immediately post-PTRA, 27 hours post-PTRA and 8 weeks post-PTRA</time_frame>
        <population>All participants for whom diastolic blood pressure was measured.</population>
        <group_list>
          <group group_id="O1">
            <title>Bendavia</title>
            <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Change in Diastolic Blood Pressure</title>
          <description>Mean Change in Diastolic Blood Pressure (DBP) values (mmHg) from baseline (pre-PTRA), immediately post-PTRA, 27 hours and 8 weeks post-PTRA, with and without Bendavia.</description>
          <population>All participants for whom diastolic blood pressure was measured.</population>
          <units>mmHg</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="7"/>
                <count group_id="O2" value="9"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>27 Hours Post-PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="7"/>
                    <count group_id="O2" value="9"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="3.6" spread="7.76"/>
                    <measurement group_id="O2" value="-2.0" spread="9.88"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>8 Weeks Post PTRA</title>
              <analyzed_list>
                <analyzed>
                  <units>Participants</units>
                  <scope>Class</scope>
                  <count_list>
                    <count group_id="O1" value="6"/>
                    <count group_id="O2" value="8"/>
                  </count_list>
                </analyzed>
              </analyzed_list>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="0.0" spread="9.70"/>
                    <measurement group_id="O2" value="0.1" spread="9.80"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Bendavia</title>
          <description>Bendavia, intravenous infusion, 0.05 mg/kg/hr for a maximum duration of 4 hours.</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>Placebo (no active drug), intravenous infusion, for a maximum duration of 4 hours.</description>
        </group>
      </group_list>
      <serious_events>
        <default_vocab>MedDRA 18.0</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Cardiac disorders</title>
            <event_list>
              <event>
                <sub_title vocab="MedDRA (18.0)">Cardiac Failure Acute</sub_title>
                <counts group_id="E1" events="0" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" events="2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Vascular Pseudoaneurysm</sub_title>
                <counts group_id="E1" events="1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" events="0" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_vocab>MedDRA (18.0)</default_vocab>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="2" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="5" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Gastrointestinal disorders</title>
            <event_list>
              <event>
                <sub_title>Constipation</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Oedema peripheral</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Pneumonia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Injury, poisoning and procedural complications</title>
            <event_list>
              <event>
                <sub_title>Contusion</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Procedural Pain</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Investigations</title>
            <event_list>
              <event>
                <sub_title>Blood sodium decreased</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood magnesium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Blood potassium decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Pedal pulse decreased</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Thyroid function test abnormal</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Metabolism and nutrition disorders</title>
            <event_list>
              <event>
                <sub_title>Hyperphosphataemia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Nervous system disorders</title>
            <event_list>
              <event>
                <sub_title>Dizziness</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Presyncope</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Psychiatric disorders</title>
            <event_list>
              <event>
                <sub_title>Anxiety</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Insomnia</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Respiratory, thoracic and mediastinal disorders</title>
            <event_list>
              <event>
                <sub_title>Cough</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Nasal Dryness</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Respiratory Distress</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="2" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Vascular disorders</title>
            <event_list>
              <event>
                <sub_title>Hypertension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Hypotension</sub_title>
                <counts group_id="E1" subjects_affected="1" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
              <event>
                <sub_title>Labile Blood Pressure</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="7"/>
                <counts group_id="E2" subjects_affected="1" subjects_at_risk="9"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>The only disclosure restriction on the PI is that the sponsor can review results communications prior to public release and can embargo communications regarding trial results for a period that is less than or equal to 60 days. The sponsor cannot require changes to the communication and cannot extend the embargo.</restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Jim Carr, Pharm.D. Chief Clinical Development Officer</name_or_title>
      <organization>Stealth BioTherapeutics, Inc</organization>
      <phone>1-617-600-6888</phone>
      <email>jim.carr@stealthbt.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

